Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
John Burnett
Mayo Clinic Rochester, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Zumbro Discovery, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Please see attached.
Novel Peptide Therapeutics for Hypertension
PROJECT NARRATIVE We propose to advance novel therapeutic designer peptides engineered by the applicants that targets the natriuretic peptide/pGC receptor-A/cGMP system for the treatment of resistant hypertension (RH). We will test MANP in African Americans who are at increased risk for RH and adverse cardiorenal outcomes. We also will define the cardiorenal and RAAS suppressing actions of a second-generation peptide called MANP2 in experimental hypertension. Finally, we will establish for the first time the ability to optimize this pathway by combining MANP2 and novel small molecule positive allosteric modulators representing an innovative synergism between a small molecule and therapeutic peptide.
Filed on May 07, 2018.
Tell us what you know about John Burnett's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
John Burnett filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| John Burnett | Mayo Clinic Rochester | Conflict of Interest | Capricor Therapeutics, Inc. | $10,000 - $19,999 |
| John Burnett | Mayo Clinic Rochester | Conflict of Interest | Zumbro Discovery, Inc. | Value cannot be readily determined |
| John Burnett | Mayo Clinic Rochester | Conflict of Interest | Zumbro Discovery | Value cannot be readily determined |
| John Burnett | Mayo Clinic Rochester | Conflict of Interest | Zumbro Discovery | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.